Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

16 novembre 2026 mis à jour par: Cogent Biosciences, Inc.

Une étude clinique de phase 3 randomisée, ouverte et multicentrique comparant CGT9486 + sunitinib à sunitinib chez des sujets atteints de tumeurs stromales gastro-intestinales localement avancées, non résécables ou métastatiques

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

482

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Bad Saarow, Allemagne, 15526
        • Actif, ne recrute pas
        • Helios Klinikum Bad Saarow
      • Berlin, Allemagne, 13125
        • Actif, ne recrute pas
        • Helios Klinikum Berlin-Buch
      • Essen, Allemagne, 45147
        • Actif, ne recrute pas
        • Universitaetsklinikum Essen
      • Hamburg, Allemagne, 20246
        • Actif, ne recrute pas
        • Universitaetsklinikum Hamburg-Eppendorf
      • Hanover, Allemagne, 30625
        • Actif, ne recrute pas
        • Medizinische Hochschule Hannover- Urology Oncology
      • Mannheim, Allemagne, 68167
        • Actif, ne recrute pas
        • Universitaetsmedizin Mannheim
      • Buenos Aires, Argentine, C1426ANZ
        • Actif, ne recrute pas
        • Instituto Alexander Fleming
      • Córdoba, Argentine, X5000HWE
        • Actif, ne recrute pas
        • Instituto Oncologico de Cordoba (IONC)
      • Bankstown, Australie, 2200
        • Actif, ne recrute pas
        • Bankstown-Lidcombe Hospital
    • Western Australia
      • Nedlands, Western Australia, Australie, 6009
        • Actif, ne recrute pas
        • Sir Charles Gairdner Hospital
      • Campinas, Brésil, 130.83-888
        • Actif, ne recrute pas
        • Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
      • Rio de Janeiro, Brésil, 20.230-130
        • Actif, ne recrute pas
        • lnstituto Nacional de Cancer - INCA
      • São Paulo, Brésil, 09060-650
        • Actif, ne recrute pas
        • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
      • Calgary, Canada, T2N 4N2
        • Recrutement
        • Tom Baker Cancer Center
      • Montreal, Canada, HIT 2M4
        • Actif, ne recrute pas
        • Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Recrutement
        • Alberta Health Services Cross Cancer Institute
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Princess Margaret Hospital
      • Santiago, Chili, 7500921
        • Actif, ne recrute pas
        • Instituto Oncologico FALP
      • Santiago, Chili, 7560908
        • Actif, ne recrute pas
        • Centro de Oncologia de Precision, Universidad Mayor
      • Seoul, Corée du Sud, 03080
        • Actif, ne recrute pas
        • Seoul National University Hospital
      • Seoul, Corée du Sud, 06351
        • Actif, ne recrute pas
        • Samsung Medical Center
      • Seoul, Corée du Sud, 08308
        • Actif, ne recrute pas
        • Korea University Guro Hospital
      • Seoul, Corée du Sud, 05505
        • Actif, ne recrute pas
        • Asan Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Corée du Sud, 10408
        • Retiré
        • National Cancer Center
      • Aarhus, Danemark, 8200
        • Actif, ne recrute pas
        • Aarhus University Hospital
      • Barcelona, Espagne, 08035
        • Actif, ne recrute pas
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Espagne, 08041
        • Retiré
        • Hospital de la Santa Creu i Sant Pau Barcelona
      • Barcelona, Espagne, 08908
        • Actif, ne recrute pas
        • Institut Catala d'Oncologia - L'Hospitalet
      • El Palmar, Espagne, 30120
        • Retiré
        • Hospital Clinico Universitario Virgen de la Arrixaca
      • Madrid, Espagne, 28041
        • Actif, ne recrute pas
        • Hospital Universitario 12 de Octubre
      • Madrid, Espagne, 28040
        • Actif, ne recrute pas
        • Hospital Clinico San Carlos
      • Madrid, Espagne, 28007
        • Actif, ne recrute pas
        • Hospital General Universitario Gregorio Maranon
      • Madrid, Espagne, 28040
        • Actif, ne recrute pas
        • Hospital Fundación Jiménez Díaz
      • Santiago de Compostela, Espagne, 15706
        • Actif, ne recrute pas
        • Hospital Clinico Universitario de Santiago de Compostela
      • Seville, Espagne, 41013
        • Actif, ne recrute pas
        • Hospital Universitario Virgen del Rocio
      • Zaragoza, Espagne, 50009
        • Retiré
        • Hospital Universitario Miguel Servet
      • Bordeaux, France, 33076
        • Actif, ne recrute pas
        • Institut Bergonie
      • Lille, France, 59000
        • Actif, ne recrute pas
        • Centre Oscar Lambret
      • Lyon, France, 69008
        • Actif, ne recrute pas
        • Centre Leon Berard
      • Marseille, France, 13005
        • Actif, ne recrute pas
        • AP-HM - Hôpital de la Timone
      • Rennes, France, 35042
        • Actif, ne recrute pas
        • Centre Eugene Marquis
      • Saint-Herblain, France, 44800
        • Actif, ne recrute pas
        • ICO St-Herblain
      • Toulouse, France, 31400
        • Actif, ne recrute pas
        • CHU de Toulouse - Hospital Rangueil
      • Villejuif, France, 94805
        • Actif, ne recrute pas
        • Gustave Roussy
      • Central, Hong Kong
        • Retiré
        • Humanity & Health Clinical Trial Centre
      • Jordon, Hong Kong
        • Actif, ne recrute pas
        • Hong Kong United Oncology Centre
      • Shatin, Hong Kong
        • Actif, ne recrute pas
        • Prince of Wales Hospital
      • Debrecen, Hongrie, 4032
        • Actif, ne recrute pas
        • Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
      • Aviano, Italie, 33081
        • Actif, ne recrute pas
        • Centro Riferimento Oncologico - Aviano
      • Bologna, Italie, 40138
        • Actif, ne recrute pas
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
      • Brescia, Italie, 25123
        • Actif, ne recrute pas
        • ASST degli Spedali Civili di Brescia
      • Candiolo, Italie, 10060
        • Retiré
        • IRCCS La Fondazione e l'Istituto di Candiolo
      • Florence, Italie, 50134
        • Actif, ne recrute pas
        • Azienda Ospedaliero-Universitaria Careggi
      • Meldola, Italie, 47014
        • Actif, ne recrute pas
        • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
      • Milan, Italie, 20133
        • Actif, ne recrute pas
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, Italie, 20141
        • Actif, ne recrute pas
        • Istituto Europeo di Oncologia
      • Palermo, Italie, 90127
        • Actif, ne recrute pas
        • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
      • Roma, Italie, 00128
        • Actif, ne recrute pas
        • Policlinico Universitario Campus Bio-Medico
      • Rozzano, Italie, 20089
        • Actif, ne recrute pas
        • Istituto Clinico Humanitas
      • Verona, Italie, 31726
        • Actif, ne recrute pas
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Aguascalientes, Mexique, 20116
        • Retiré
        • Centro de Investigacion Medica Aquascalientes (CIMA)
      • Monterrey, Mexique, 64710
        • Actif, ne recrute pas
        • I Can Oncology Center SA De CV
      • Oaxaca City, Mexique, 68000
        • Retiré
        • Oaxaca Site Management Organization S.C.
      • Bergen, Norvège, 5021
        • Actif, ne recrute pas
        • Haukeland University Hospital - Bergen
      • Oslo, Norvège, 0310
        • Actif, ne recrute pas
        • Oslo University Hospital
      • Amsterdam, Pays-Bas, 1066 CX
        • Actif, ne recrute pas
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
      • Groningen, Pays-Bas, 9713 GZ
        • Actif, ne recrute pas
        • UMC Groningen
      • Nijmegen, Pays-Bas, 6525 GA
        • Actif, ne recrute pas
        • Stichting Radboud Universitair Medisch Centrum
      • Rotterdam, Pays-Bas, 3015 GD
        • Actif, ne recrute pas
        • Erasmus MC
      • Brzozów, Pologne, 36-200
        • Actif, ne recrute pas
        • Szpital Specjalistyczny w Brzozowie
      • Bydgoszcz, Pologne, 85-796
        • Retiré
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka
      • Gliwice, Pologne, 44-102
        • Actif, ne recrute pas
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
      • Warsaw, Pologne, 02-781
        • Actif, ne recrute pas
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
      • Cambridge, Royaume-Uni, CB2 0QQ
        • Actif, ne recrute pas
        • Cambridge Addenbrooke's Hospital
      • Glasgow, Royaume-Uni, G12 0YN
        • Retiré
        • Beatson, West of Scotland Cancer Centre
      • London, Royaume-Uni, NW1 2PG
        • Actif, ne recrute pas
        • University College London Hospital
      • London, Royaume-Uni, SW3 6JJ
        • Actif, ne recrute pas
        • Royal Marsden Hospital - Surrey
      • London, Royaume-Uni, SE1 9RT
        • Retiré
        • Guy's Hospital
      • Manchester, Royaume-Uni, M20 4BX
        • Actif, ne recrute pas
        • The Christie NHS Foundation Trust
      • Sheffield, Royaume-Uni, S10 2SJ
        • Actif, ne recrute pas
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Lund, Suède, 22185
        • Actif, ne recrute pas
        • Skane University Hospital Lund
      • Solna, Suède, 171 76
        • Actif, ne recrute pas
        • Karolinska University Hospital
      • Kaohsiung City, Taïwan, 83301
        • Actif, ne recrute pas
        • Chang Gung Memorial Hospital - Kaohsiung Branch
      • New Taipei City, Taïwan, 10002
        • Actif, ne recrute pas
        • National Taiwan University Hospital
      • Taichung, Taïwan, 40447
        • Actif, ne recrute pas
        • China Medical University Hospital
      • Taipei, Taïwan, 11217
        • Actif, ne recrute pas
        • Taipei Veterans General Hospital (VGHTP)
      • Taoyuan, Taïwan, 33305
        • Actif, ne recrute pas
        • Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
      • Brno, Tchéquie, 65653
        • Actif, ne recrute pas
        • Masarykuv onkologicky ustav
      • Hradec Králové, Tchéquie, 500 05
        • Retiré
        • Fakultni nemocnice Hradec Kralove
      • Olomouc, Tchéquie, 77900
        • Actif, ne recrute pas
        • Fakultni nemocnice Olomouc - Oncology clinic
    • Alabama
      • Birmingham, Alabama, États-Unis, 35249
        • Retiré
        • University of Alabama at Birmingham
    • Arizona
      • Scottsdale, Arizona, États-Unis, 85259
        • Recrutement
        • Mayo Clinic
      • Tucson, Arizona, États-Unis, 85719
        • Actif, ne recrute pas
        • University of Arizona- Cancer Center
    • California
      • Duarte, California, États-Unis, 91010
        • Recrutement
        • City of Hope
      • Los Angeles, California, États-Unis, 90404
        • Actif, ne recrute pas
        • University of California, Los Angeles (UCLA)
      • San Diego, California, États-Unis, 92093
        • Recrutement
        • University of California, San Diego (UCSD)
      • San Francisco, California, États-Unis, 94158
        • Actif, ne recrute pas
        • University of California, San Francisco
    • Colorado
      • Denver, Colorado, États-Unis, 80204
        • Recrutement
        • University of Colorado Denver
    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20010
        • Recrutement
        • MedStar Washington Hospital Center
    • Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Recrutement
        • Mayo Clinic Jacksonville
      • Miami, Florida, États-Unis, 33136
        • Recrutement
        • University of Miami - Sylvester Comprehensive Cancer Center
      • Orange City, Florida, États-Unis, 32763
        • Retiré
        • Mid Florida Hematology and Oncology Center
      • Orlando, Florida, États-Unis, 32806
        • Recrutement
        • Orlando Health Cancer Institute
      • Tampa, Florida, États-Unis, 33612
        • Recrutement
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Northwestern University
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • Recrutement
        • University of Iowa Hospital and Clinics
    • Kansas
      • Kansas City, Kansas, États-Unis, 66160
        • Actif, ne recrute pas
        • University of Kansas Cancer Center
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Recrutement
        • Dana-Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Recrutement
        • University of Michigan Comprehensive Cancer Center
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, États-Unis, 63130
        • Recrutement
        • Washington University
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68114
        • Recrutement
        • Nebraska Methodist Hospital
    • New York
      • Buffalo, New York, États-Unis, 14203
        • Actif, ne recrute pas
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, États-Unis, 10021
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Duke University
    • Ohio
      • Cleveland, Ohio, États-Unis, 44195
        • Recrutement
        • The Cleveland Clinic Foundation
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • The Ohio State University Comprehensive Cancer Center
      • Toledo, Ohio, États-Unis, 43614
        • Retiré
        • University of Toledo Medical Center
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Recrutement
        • Oregon Health & Science University (OHSU)
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19111
        • Recrutement
        • Fox Chase Cancer Center
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Recrutement
        • University of Pittsburgh Medical Center - Hillman Cancer Center
    • Tennessee
      • Knoxville, Tennessee, États-Unis, 37920
        • Retiré
        • University of Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Recrutement
        • Vanderbilt University Medical Center
    • Texas
      • Houston, Texas, États-Unis, 77030-4009
        • Recrutement
        • The University of Texas MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Actif, ne recrute pas
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Madison, Wisconsin, États-Unis, 53705
        • Recrutement
        • University of Wisconsin - Carbone Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)

  2. Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)

  3. Participants must have received the following treatment:

    • DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
    • Part 1b: Treatment with ≥2 prior TKI for GISTs
    • Part 2: Prior treatment with imatinib only
    • GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
  4. Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)

  5. Eastern Cooperative Oncology Group (ECOG) Status

    • 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
    • 0 to 1 (GIST 1L Substudy)
  6. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits

Key Exclusion Criteria:

  1. Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
  2. Clinically significant cardiac disease
  3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
  4. Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
  5. Any active bleeding excluding hemorrhoidal or gum bleeding
  6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
  7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
  8. Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
  9. Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1a

Bezuclastinib plus sunitinib 37.5 mg once a day (QD)

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Expérimental: Part 2 - Experimental Group

Bezuclastinib plus sunitinib 37.5 mg QD

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Comparateur actif: Part 2 - Control Group

Sunitinib 37.5 mg QD

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Expérimental: Part 1b - DDI Cohort 1

Bezuclastinib plus sunitinib 37.5 mg QD

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Expérimental: Part 1b - DDI Cohort 2

Sunitinib 37.5 mg QD plus bezuclastinib

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Expérimental: DDI Substudy (Midazolam)

Midazolam, bezuclastinib, sunitinib

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Participants will receive a single-dose of midazolam on Day 1 and Day 15

Expérimental: GIST 1L Substudy

Bezuclastinib, sunitinib

Participants will receive bezuclastinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

Autres noms:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part 1a - pharmacokinetics - Cmax
Délai: 16 days

Maximum plasma concentration (Cmax)

16 days
Part 1a - pharmacokinetics - AUC
Délai: 16 days

Area under the plasma concentration-time curve (AUC)

16 days
Part 1b - pharmacokinetics - Cmax
Délai: 14 days

Maximum plasma concentration (Cmax)

14 days
Part 1b - pharmacokinetics - AUC
Délai: 14 days

Area under the plasma concentration-time curve (AUC)

14 days
Part 1b - pharmacokinetics - Tmax
Délai: 14 days

Time to maximum observed plasma concentration (Tmax)

14 days
Part 2 - Progression Free Survival (PFS)
Délai: Approximately 48 months

Time from first dose to documented disease progression or death due to any cause, whichever occurs first

Approximately 48 months
DDI Substudy - pharmacokinetics - AUC
Délai: 16 days

Area under the plasma concentration-time curve (AUC)

16 days
DDI Substudy - pharmacokinetics - Cmax
Délai: 14 days

Maximum plasma concentration (Cmax)

14 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
All Study Parts - observing the safety of each treatment regimen.
Délai: Approximately 48 months

Incidence and severity of Adverse Events from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
Délai: Approximately 48 months

Incidence and severity of Serious Adverse Events from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
Délai: Approximately 48 months

Incidence of Adverse Events leading to dose modifications from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
Délai: Approximately 48 months

Change from baseline in laboratory results

Approximately 48 months
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
Délai: Approximately 48 months

Time from first dose to death due to any cause

Approximately 48 months
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
Délai: Approximately 48 months

Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Approximately 48 months
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
Délai: Approximately 48 months

Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks

Approximately 48 months
Part 1a, Part 1b. Part 2 - Time to response (TTR)
Délai: Approximately 48 months

Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1

Approximately 48 months
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
Délai: Approximately 48 months

Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first

Approximately 48 months
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Délai: Approximately 48 months

Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms.

Approximately 48 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 avril 2022

Achèvement primaire (Réel)

30 septembre 2025

Achèvement de l'étude (Estimé)

1 janvier 2030

Dates d'inscription aux études

Première soumission

23 décembre 2021

Première soumission répondant aux critères de contrôle qualité

14 janvier 2022

Première publication (Réel)

26 janvier 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner